Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

ATF4:p52 Complex activates oncogenic enhancers in multiple myeloma via p300/CBP recruitment to regulate BACH1

Ang, Daniel Aron, Harmston, Nathan and Li, Yinghui 2025. ATF4:p52 Complex activates oncogenic enhancers in multiple myeloma via p300/CBP recruitment to regulate BACH1. Cancer Letters 623 , 217727. 10.1016/j.canlet.2025.217727
Item availability restricted.

[thumbnail of 1-s2.0-S0304383525002939-main.pdf.pdf] PDF - Accepted Post-Print Version
Restricted to Repository staff only until 16 April 2026 due to copyright restrictions.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB)

Abstract

Multiple myeloma (MM) is a B-cell malignancy accounting for 20 % of all blood-associated cancers. MM patients with a poorer prognosis and high-risk stratification were previously observed to be causally linked to the constitutive activation of non-canonical NF-κB (ncNF-κB) pathway. Consistent with this, the ncNF-κB p52 transcription factor was earlier found to regulate the enhancer landscape of MM to potentiate oncogenic transcription. However, the mechanism by which aberrant p52 expression is involved in coordinating enhancer activity has not been well explored. In this study, we analysed H3K27ac ChIP-seq and ATAC-seq data from MM cell lines and patient samples to screen for putative transcription factors that cooperate with p52 to regulate enhancers activated in MM. We report that ATF4 interacts with p52 and together, this complex mediates the activity of a subset of MM-associated enhancers through the recruitment of histone acetyltransferases (HATs), p300 and CBP (CREB-binding protein). We also identified a ATF4:p52 regulated target gene BACH1 under the regulation of a proximal super-enhancer, which was found to drive oncogenesis in MM by promoting cell cycle progression and proliferation. Together, our findings provide further mechanistic insights into how aberrant enhancer activation observed in MM tumours could lead to disease progression.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Schools > Biosciences
Publisher: Elsevier
ISSN: 0304-3835
Date of First Compliant Deposit: 1 May 2025
Date of Acceptance: 16 April 2025
Last Modified: 28 May 2025 09:15
URI: https://orca.cardiff.ac.uk/id/eprint/178014

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics